Vivici, a Dutch startup backed by multinational dsm-firmenich and dairy multinational Fonterra, has raised €32.5 million in a Series A funding round. The financing round was led by APG - on behalf of pension fund ABP - and Invest-NL. With this investment, Vivici can take the next step towards further scaling up and commercialization.
Vivici was founded in 2023 with the mission to realize the commercial potential of precision fermentation. Precision fermentation – the method Vivici uses to make dairy protein – combines the process of traditional fermentation with modern biotechnology. This technology makes it possible to produce high-quality proteins without the use of animals. In this way, the company meets the protein needs of a growing world population in a sustainable way, without compromising on price, taste or nutritional value.
Sports nutrition
The funding round was led by APG - on behalf of Pensioenfonds ABP - and Invest-NL. Innovation Quarter also participated in the investment round, in addition to existing shareholders dsm-firmenich and Fonterra. With this capital, Vivici can expand internationally, launch a second dairy protein ingredient and build long-term production capacity.
Vivici's first ingredient, ViviteinTM BLG, is specifically focused on sports nutrition, a fast-growing market worth US$28.4 billion worldwide. With product innovations such as clear water-based protein drinks and vegan bars with similar properties to bars made with animal-derived ingredients, ViviteinTM BLG opens up new commercial opportunities within the sports nutrition.